H.C. Wainwright Reiterates Buy Rating on CorMedix (CRMD)
H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $13.00 price target on CorMedix (NASDAQ: CRMD).The analyst commented: "We ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)